Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
ln Vitro |
The human ACMSD inhibitor TES-1025, which has a low nanomolar concentration, raises NAD+ levels in cellular systems [1].
|
---|---|
ln Vivo |
Male CD-1 mice were used for in vivo pharmacokinetic investigations of TES-1025 after both intravenous (IV) and oral (PO) treatment. TES-1025 demonstrated poor blood clearance, low volume of distribution, and a half-life (t1/2) of roughly 5.33 hours following an intravenous administration of 0.5 mg/kg. On the other hand, the quantitative time of TES-1025 plasma concentration was up to 8 hours following oral dose of 5 mg/kg. For TES-1025, good systemic exposure was reported, and two hours after dosage, a Cmax of 2570 ng/mL was attained. The liver and kidney have higher oral exposure to TES-1025, with AUC0-8h values of 19 200 h·ng/mL and 36 600 h·ng/mL, respectively [1].
|
References |
[1]. Pellicciari R, et al. α-Amino-β-carboxymuconate-ε-semialdehyde Decarboxylase (ACMSD) Inhibitors as Novel Modulators of De Novo Nicotinamide Adenine Dinucleotide (NAD+) Biosynthesis. J Med Chem. 2018 Feb 8;61(3):745-759
|
Molecular Formula |
C18H13N3O3S2
|
---|---|
Molecular Weight |
383.44412112236
|
Exact Mass |
383.039
|
Elemental Analysis |
C, 56.38; H, 3.42; N, 10.96; O, 12.52; S, 16.72
|
CAS # |
1883602-21-8
|
PubChem CID |
137142885
|
Appearance |
Solid powder
|
LogP |
2.5
|
Hydrogen Bond Donor Count |
2
|
Hydrogen Bond Acceptor Count |
7
|
Rotatable Bond Count |
6
|
Heavy Atom Count |
26
|
Complexity |
695
|
Defined Atom Stereocenter Count |
0
|
InChi Key |
RJQYGCGMQYVVIB-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C18H13N3O3S2/c19-9-13-16(14-5-2-6-25-14)20-18(21-17(13)24)26-10-12-4-1-3-11(7-12)8-15(22)23/h1-7H,8,10H2,(H,22,23)(H,20,21,24)
|
Chemical Name |
2-[3-[(5-cyano-6-oxo-4-thiophen-2-yl-1H-pyrimidin-2-yl)sulfanylmethyl]phenyl]acetic acid
|
Synonyms |
TES1025; TES 1025; TES-1025
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~260.80 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.52 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.6080 mL | 13.0398 mL | 26.0797 mL | |
5 mM | 0.5216 mL | 2.6080 mL | 5.2159 mL | |
10 mM | 0.2608 mL | 1.3040 mL | 2.6080 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.